Couldn’t agree more here! This is why our multiplex edits solve both biology and mfg issues that have plagued solid tumor cell tx scaling “T cell therapies work,” he said. “It’s a matter of scaling these across targets and getting the manufacturing to a scalable point as well.”

Just launched our revamped KiraGen Bio website. We’re building multiplex-edited CAR-T that act like noise-cancelling headphones for cell therapies—ignoring tumor suppression so our cells keep working. Take a look → kiragenbio.com

The founder’s journey is mostly a solo one. You carry the weight when no one else can. But the resonance--the way success ripples out to your team, your customers, your community--makes it worth it. That’s the paradox: alone in the struggle, together in the success.

If you don’t already follow Sara, do so today. Her posts are always a valuable look into what is really going on, and while they look long, the depth is appreciated!

This GD2 CAR-T neuroblastoma paper gives our field something rare: genuine hope. 40% complete remission 78% alive at 5 years Kids still cancer-free more 5+ years after one infusion This isn’t a promise for “someday.” Ex vivo solid tumor CAR-T is arriving — and it’s here now.

Aaron Edwards Shared the Results on GD2 CAR-T in Neuroblastoma Aaron Edwards oncodaily.com/science/gd2-ca… #Cancer #ImmuneOnc #IO #ImmunoOncology #Immunotherapy #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

Will in Vivo CAR-T Make Everything Else Obsolete? - Aaron Edwards oncodaily.com/voices/aaron-e… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX

Striking insights from Oliver Hahn & team at Calico! Young microglia transplanted into old brains aged rapidly due to environmental cues — driven by NK cell–mediated interferon signaling. Blocking Stat1 protected donor cells, showing how pre-programmed edits can resist

Agree 100%. China’s speed & cost edge is undeniable—so leverage it for early trials. Separately, we need to re-shore mfg with the right incentives. As June Park outlines: disincentivize foreign IP dependence, rebuild domestic capacity, and double down on U.S. science + talent.

Exactly this. Ryan Murray, PhD and I wake up every day focused on KiraGen Bio—fighting glioblastoma and other suppressive cancers where patients urgently need new hope. Nothing else feels like a job worth doing.

They said it was impossible: -Multiplex CAR-T -GBM "undruggable" -AI + affordable CGT They were wrong. At KiraGen Bio, we’re engineering cells with noise-cancelling headphones that let them ignore tumor suppression & keep fighting. Making the "impossible" → inevitable.

Seen at KiraGen Bio office today: salads for “longevity”, Coke Zero powering our experiment planning, and our newest team member rocking noise-cancelling headphones to tune out tumor noise 🎧🧬

BREAKING NEWS❗ NIH establishes nation's first dedicated organoid development center to reduce reliance on animal modeling. bit.ly/4pBYT9T

Do not lick sodium

A pleasure meeting Brad Loncar — the OG biotech storyteller. Excited to share how KiraGen Bio uses AI-guided multiplex editing to equip cell therapies with noise-cancelling headphones against tumor suppression — keeping them durable, focused, and on mission!

Great meeting @supachaimd (Dr. Kid) from @seaxventures. He’s building critical US biotech infrastructure — a SE Asia clinical-trial hub for FIH data and pathways for next-gen therapies into markets once out of reach. From RISE to SEA Hub, laying groundwork for global scale.

Scientists often generate novel hypotheses about cancer cellular behavior, which are experimentally validated in living cells.

Kicked off Creative Destruction Lab (CDL) Advanced Tx in Toronto. Great seeing familiar faces & meeting new ones; my intro to Canadian biotech. Founders sharing lessons, investors giving feedback, builders making connections. Our "noise-cancelling headphones for cell therapies" got some ❤️ too!

To everyone who’s shared a story about someone they love affected by GBM—thank you. We see you. Your stories drive our work at KiraGen Bio. We’re building so that one day, fewer people will have to tell them.